Drug firm Glenmark Pharmaceuticals today said it has suspended clinical trial at the Malpani Hospital in Jaipur as soon as it became aware of the alleged irregularities at the hospital.
The company has "received the show-cause notice pertaining to the monitoring of the clinical trial at Malpani Hospital...," Glenmark Pharmaceuticals said in a BSE filing.
Coming out with a clarification on the news reports regarding clinical trial, the company said," As soon as the company became aware of the alleged irregularities at Malpani Hospital, the trials at the site were immediately suspended in the interest of patient safety."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app